CN106540250A - The preparation method of goose source reovirus inactivated vaccine - Google Patents
The preparation method of goose source reovirus inactivated vaccine Download PDFInfo
- Publication number
- CN106540250A CN106540250A CN201611076819.1A CN201611076819A CN106540250A CN 106540250 A CN106540250 A CN 106540250A CN 201611076819 A CN201611076819 A CN 201611076819A CN 106540250 A CN106540250 A CN 106540250A
- Authority
- CN
- China
- Prior art keywords
- preparation
- goose
- inactivated vaccine
- water
- jing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a kind of preparation method of goose source reovirus inactivated vaccine, comprises the following steps：Reoviruses Jing allantoic cavitys are inoculated with into goose embryo, dead germ or embryo allantoic liquid living in 24～144 hours are collected after incubation, virus liquid is obtained；By the virus liquid Jing formalin-inactivateds, add Tween 80 to mix as water phase, mixed as oil phase using white oil, Span 80 and aluminium stearate, water is added to into oil phase mix homogeneously, inactivated vaccine is obtained.Goose source reovirus inactivated vaccine prepared by the present invention has higher Vaccine effectiveness to young goose, it is adaptable to the virus immunity to young goose.
Description
Technical field
The invention belongs to veterinary vaccine technical field, more particularly to a kind of preparation side of goose source reovirus inactivated vaccine
Method.
Background technology
Geese reovirus infection is a kind of goose viral infectious caused by geese reovirus.
Reoviridae (Reovirdae) includes Orthoreovirus (Orthoreovirus), rotaviruses
(Rotavirus), Orbiviruses (orbivirus), cypovirus (Cypovirus), Phytoreovirus
Category (Phytoreovirus) and Fijivirus category (Fijivirus).Orthoreovirus is large numbers of double-strands with cyst membrane
RNA viruses, current study show that, cause goose infection morbidity for Reoviridae, the goose of Orthoreovirus subgroup II
Reoviruses.
The prevalence of geese reovirus infection betides the young goose and green goose of 1 week old to 10 week old without obvious seasonality, many
Betide the young goose of 2～4 week old.M ＆ M has close relationship with age in days, differs greatly.Sickness rate be 10%～
70%, the less sickness rate of age in days is higher, and mortality rate is 2%～60%, and in 3 week old, after young goose infection, mortality rate is higher, 7～10 weeks
After the infection of age green goose, mortality rate is low.The disease can vertical transmission and horizontal transmission.Fecal pollution is the main source of contact stain.
The many down in spirits of sick goose, appetite subtract greatly or useless exhausted, and feather is matt in a jumble, weak, becomes thin, and is slow in action or lame
OK, one or both sides plantar joint or tarsal joint swelling.Acute onset shows as splenitis, and spleen has the granular necrosis region of foxtail millet.It is subacute
Or chronic phase morbidity goose shows as pericarditiss, arthritis and tenosynovitiss.
Immunity is carried out using inactivated vaccine, is one of the prevention and control sick effective measures.At present, the lonely disease of intestinal is exhaled for goose
The still no reasonable vaccine of poison.
The content of the invention
In view of this, it is an object of the invention to provide a kind of preparation method of goose source reovirus inactivated vaccine, sheet
Goose source reovirus inactivated vaccine prepared by the method that invention is provided can prevent and control geese reovirus to infect.
The invention provides a kind of preparation method of goose source reovirus inactivated vaccine, comprises the following steps：
Reoviruses Jing allantoic cavitys are inoculated with into goose embryo, dead germ or embryo allantoic liquid living in 24～144 hours after incubation, is collected,
Obtain virus liquid；
By the virus liquid Jing formalin-inactivateds, Tween-80 is added to mix as water phase, with white oil, Span-80 and Hard Fat
Sour aluminum mixes as oil phase, and water is added to oil phase mix homogeneously, inactivated vaccine is obtained.
Preferably, the goose embryo is 12 age in days goose embryos.
Preferably, the inoculum concentration of the reoviruses is every piece of 0.2mL.
Preferably, the temperature of the incubation is 37 DEG C.
Preferably, the virus liquid Jing formalin-inactivateds are specially：
The virus liquid is mixed with formaldehyde, 37 DEG C of standing 36h, with sodium thiosulfate terminating reaction.
Preferably, the concentration of the formaldehyde is 0.2wt%；The concentration of the sodium thiosulfate is 2wt%.
Preferably, in the water phase Tween-80 final concentration of 4wt%.
Preferably, the ratio of the white oil, Span-80 and aluminium stearate is 94:6:2.
Preferably, the mass ratio of the oil phase and water phase is 2:1.
Preferably, the mixing speed that the oil phase is mixed with water conjunction is 3000 turns/min, and the time is 30min.
Specifically, the present invention prepares inactivated vaccine in accordance with the following methods and which is tested：
1st, the preparation of oil emulsion inactivated vaccine
Reoviruses separation strains Jing allantoic cavity is inoculated with into 12 ages in days health goose embryo, every piece of 0.2mL, 37 DEG C of incubations are discarded
Dead germ in 24h, collects dead germ or embryo allantoic liquid living in 24～144 hours, subpackage be stored in -80 DEG C it is standby.
By allantoic fluid with 0.2% formalin-inactivated of final concentration, 37 DEG C of 36h are placed in, with 2% sodium thiosulfate terminating reaction.Plus
Enter the Tween-80 of sterilizing, final concentration 4%, as water phase after mixing.With white oil, Span-80, and aluminium stearate mixing are used as oil
Water is mutually poured slowly under 3000 turns of rotating speed in oil phase and is mixed by phase, and oil-water ratio is 2：1, stir 30 minutes, obtain inactivating epidemic disease
Seedling, and make correlated quality identification.
2nd, the preparation of rabbit-anti goose HRP ELIAS secondary antibody
Goose serum Jing saturated ammonium sulfates method is purified, repeatedly immunity new zealand rabbit.The rabbit anteserum for obtaining is by saturated ammonium sulfate
Method is purified.HRP labelling is carried out to purifying antibody using sodium periodate method, OD is detected with spectrophotometer280nmAnd OD403nmCarry out
Quality Identification.
3rd, ELISA detections program
Viral allantoic fluid is coated with 96 hole elisa Plates according to 100 μ L/ holes by 1 coating, and 4 DEG C overnight；
The coated ELISA Plate of 2 board-washings adds PBST diluents, concussion washing 5 minutes to be repeated four times, get rid of according to 200 μ L/ holes
It is dry.
The ELISA Plate that 3 closings are dried adds confining liquid to close according to 200 μ L/ holes, 37 DEG C of incubation 1h, concussion washing 5 minutes,
It is repeated four times, dries.
Measuring samples are diluted 10 times with PBST diluents by 4 sample-addings, are added the ELISA Plate after drying according to 100 μ L/ holes, are put
1h is incubated in 37 DEG C, concussion washing 5 minutes is repeated four times, dries.
5 detection antibodies are by enzyme labelled antibody with PBST diluents according to volume ratio 1:After 800 dilutions, add according to 100 μ L/ holes
ELISA Plate, 37 DEG C of incubation 1h, concussion washing 5 minutes are repeated four times, dry.
6TMB colour developings add TMB nitrite ions, and per 100 μ L of hole, 37 DEG C of lucifuges develop the color 15 minutes.
7 terminate 50 μ L 2M H are added per hole2SO4Terminate liquid color development stopping is reacted, and each hole reactant liquor is read in microplate reader
OD450nmValue.
The determination of f, positive marginal value
According to formula：Yin and yang attribute marginal value=negative sample OD450Meansigma methodss+3SD (standard deviation), obtains yin and yang attribute and faces
Dividing value is 0.386.Work as OD450nmMore than 0.387, can determine whether to contain reoviruses in the positive, i.e. measuring samples.
Goose source reovirus inactivated vaccine prepared by the present invention has higher Vaccine effectiveness to young goose, it is adaptable to young goose
Virus immunity.
Specific embodiment
Embodiment
In the present invention, agents useful for same and its component are as follows：
Coating buffer：1 × carbonate buffer solution (100mL, pH=9.6)：Na2CO30.2756g, NaHCO3
0.6216g, water dissolution is settled to 100mL with distillation, pH value 9.5-9.7,4 DEG C of preservations；
PBS solution：NaCl 4.25g, NaH2PO4·2H2O 0.178g, Na2HPO4·12H2O 1.386g, use distilled water
Dissolve and be settled to 500mL, pH value 7.1-7.3；
PBST diluents：Tween-20 0.5mL are added per 1L PBS, is fully mixed；
PBST confining liquids：5g drymilk are dissolved in 100mL PBST diluents, short-term preservation is in 4 DEG C, long-term to protect
It is stored in -20 DEG C.
TMB nitrite ions：
Buffer A：Weigh 66.5063g potassium citrates, with 800mL tetra- steam water dissolution and with concentrated hydrochloric acid adjust pH value to
4.0, add 314 μ L H2O2, 1L is settled to water.4 DEG C of preservations；
Buffer B：0.2956g tetramethyl benzidines (TMB) are weighed, 0.0633g tetrabutyl ammonium borohydrides (TBABH) are molten
In 30mL dimethyl acetylamide (DMA), 4 DEG C keep in dark place；
During use, by Buffer A and Buffer B with volume ratio 39：1 ratio mixing, it is now with the current；
2M H2SO4Terminate liquid：By dense H2SO4With volume ratio 1:During 10 ratio adds distilled water, mixing is cooled to room temperature
As 2M sulfuric acid solutions.
NaIO4Solution (60mmol/L)：Weigh 1.283g NaIO4 distilled water and be settled to 100mL.
Ethylene glycol (160mmol/L)：Measure 13.4uL ethylene glycol and be diluted with water to 1.5mL.
NaBH4Solution (5mg/mL)：Take 0.05gNaBH4 water and be settled to 10mL, first with existing use.
Saturated ammonium sulfate solution (PH7.4)：Add 90g ammonium sulfate, heating for dissolving, filtered while hot, after cooling in per 100mL water
Adjust pH.
Reoviruses separation strains used by of the invention are studied to be stored in Shandong Agricultural University's Animal Science And Technology disease of poultry
The reoviruses of room.
Experimentation：
1st, the preparation of antigen
Reoviruses separation strains Jing allantoic cavity is inoculated with into 12 ages in days health goose embryo, every piece of 0.2mL, 37 DEG C of incubations are discarded
Dead germ in 24h, collects dead germ or embryo allantoic liquid living in 24～144 hours, subpackage be stored in -80 DEG C it is standby.
2nd, the preparation of inactivated vaccine
The virus liquid that step 1 is obtained is placed in 37 DEG C of 36h, with 2% sodium thiosulfate with 0.2% formalin-inactivated of final concentration
Terminating reaction.Add the Tween-80 of sterilizing, final concentration 4%, as water phase after mixing.With white oil, Span-80, and stearic acid
Aluminum mixes as oil phase, is mutually poured slowly into water in oil phase and mixes under 3000 turns of rotating speed, and oil-water ratio is 2：1, stir 30 minutes,
Obtain inactivated vaccine.
Quality Identification is carried out to the inactivated vaccine：
Steriling test：Pilot sample is taken a drop to be respectively dropped in plain agar culture medium and nutrient broth, after mixing
24h is cultivated at 37 DEG C, without growth of microorganism.
Stability test：It is centrifuged 15 minutes under 5000r rotating speeds, without layering.Viscosity is checked：1mL is drawn with 1mL suction pipes
It is vertical to release 0.5mL used time 8s, meet viscosity requirement.
Retention period check：4 DEG C, 37 DEG C are placed a period of time non-breakdown of emulsion, 4 DEG C place 6 months after immunity young bird goose still have protection
Power.
3rd, the preparation of enzyme labelled antibody and purification
Goose serum Jing saturated ammonium sulfates method is purified, repeatedly immunity new zealand rabbit.The rabbit anteserum for obtaining is by saturated ammonium sulfate
Method is purified, and obtains antibody.
5mg enzymes (HRP) are dissolved in 0.5mLddH2O, adds the NaIO of new configuration40.5mL, 4 DEG C stand 20 minutes.Add
0.16M ethylene glycol 0.5mL, room temperature lucifuge 30 minutes, terminating reaction.The above-mentioned antibody (1mg/mL) of 5mg are added to load bag filter pair
Carbonate buffer solution (PH9.5) the stirring dialysed overnight of 0.05M.Liquid in bag filter is suctioned out and adds NaBH4(5mg/mL)
0.2mL, puts 4 DEG C of 2h.Equal-volume saturated ammonium sulfate is added to mixed liquor, is centrifuged after standing 30 minutes, is abandoned supernatant.Use 0.02MPBS
(PH7.4) dissolution precipitation.
4th, optimum reaction condition
The reoviruses liquid coated elisa plate that step 1 is obtained, using virus-positive serum as antibody, with HRP enzyme marks
Antibody carries out ELISA experiments as anti antibody.Under the conditions of differential responses, enzyme labelled antibody working concentration is 1：800, confining liquid
It is the PBST containing 5% defatted milk powder, antigen, traget antibody best effort time are 1h, and TMB developing times are 15 minutes.
5th, detect program
5.1 coating virus liquids are coated with 96 hole elisa Plates according to 100 μ L/ holes, and 4 DEG C overnight；
The coated ELISA Plate of 5.2 board-washings adds PBST diluents, concussion washing 5 minutes to be repeated four times according to 200 μ L/ holes,
Dry；
The ELISA Plate that 5.3 closings are dried adds the PBST containing 1% (volume ratio) bovine serum albumin (BSA) according to 200 μ L/ holes
Confining liquid is closed, and 37 DEG C of incubation 1h, concussion washing 5 minutes are repeated four times, dry；
Measuring samples are diluted 10 times with PBST diluents by 5.4 sample-addings, add the ELISA Plate after incubation according to 100 μ L/ holes,
37 DEG C of incubation 1h are placed in, concussion washing 5 minutes is repeated four times, dries；
5.5 detection antibodies are by enzyme labelled antibody with the PBST diluents containing 1%BSA according to volume ratio 1:1000 dilutions, according to
100 μ L/ holes add ELISA Plate, 37 DEG C of incubation 1h, concussion washing 5 minutes to be repeated four times, dry；
5.6TMB colour developings add freshly prepared TMB nitrite ions, and per 100 μ L of hole, 37 DEG C of lucifuges develop the color 15 minutes；
5.7 terminate, reading adds 50 μ L 2M H per hole2SO4Color development stopping is reacted, and each hole reactant liquor is read in microplate reader
The value of OD450nm.
6th, negative and positive sex determination is judged according to calculated yin and yang attribute marginal value in the content of the invention.
Reactant liquor OD450nmMore than 0.387, in being judged as the positive, i.e. measuring samples, contain reoviruses；
Reactant liquor OD450nmLess than 0.387, in being judged as feminine gender, i.e. measuring samples, reoviruses are not contained.
Application examples
With strong virus attack 6d ages young bird goose, counteracting toxic substances dosage 0.2ml, in one week interior day, there is symptom or death, sickness rate
100%, mortality rate 70-80%.
Vaccine 0.2ml and 0.5ml prepared by 6d ages young bird goose packet intramuscular injection embodiment, 7d, 12d, 27d after immunity,
Counteracting toxic substances in batches, 5 plumage every time, per plumage 0.2ml, as a result as shown in table 1, table 1 is immune effect provided in an embodiment of the present invention.
1 immune effect provided in an embodiment of the present invention of table
As shown in Table 1, without death, 0.2ml group protective rates are higher but still have death for 0.5ml groups.
Cloaca formula and throat swab detection toxin expelling are extracted using PT-PCR methods, is as a result shown, throat swab is without detection.
The 0.2ml immune group 7dpi counteracting toxic substances cloacas positive 1/5.
Two groups of immune group gathered serum indirect ELISA detection antibody every three days, as a result showed, 0.5ml groups and 0.2ml groups
Start significantly rising when 6 days, peak within 3 weeks 1.08,1.02, be slightly decreased this two weeks after and still maintain higher level 0.99,
0.89, whole experiment recessive 0.3～0.35 of matched group, the disease mainly to 35 ages in days within young goose it is pathogenic, therefore off-test
When still have preferably protection.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of preparation method of goose source reovirus inactivated vaccine, comprises the following steps：
Reoviruses Jing allantoic cavitys are inoculated with into goose embryo, dead germ or embryo allantoic liquid living in 24～144 hours are collected after incubation, is obtained
Virus liquid；
By the virus liquid Jing formalin-inactivateds, Tween-80 is added to mix as water phase, with white oil, Span-80 and aluminium stearate
Water is added to oil phase mix homogeneously, obtains inactivated vaccine as oil phase by mixing.
2. preparation method according to claim 1, it is characterised in that the goose embryo is 12 age in days goose embryos.
3. preparation method according to claim 1, it is characterised in that the inoculum concentration of the reoviruses is per piece
0.2mL。
4. preparation method according to claim 1, it is characterised in that the temperature of the incubation is 37 DEG C.
5. preparation method according to claim 1, it is characterised in that the virus liquid Jing formalin-inactivateds are specially：
The virus liquid is mixed with formaldehyde, 37 DEG C of standing 36h, with sodium thiosulfate terminating reaction.
6. preparation method according to claim 5, it is characterised in that the concentration of the formaldehyde is 0.2wt%；It is described thio
The concentration of sodium sulfate is 2wt%.
7. preparation method according to claim 1, it is characterised in that Tween-80's is final concentration of in the water phase
4wt%.
8. preparation method according to claim 1, it is characterised in that the ratio of the white oil, Span-80 and aluminium stearate
For 94:6:2.
9. preparation method according to claim 1, it is characterised in that the mass ratio of the oil phase and water phase is 2:1.
10. preparation method according to claim 1, it is characterised in that the oil phase is mixed with water the mixing speed of conjunction and is
3000 turns/min, the time is 30min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611076819.1A CN106540250A (en) | 2016-11-30 | 2016-11-30 | The preparation method of goose source reovirus inactivated vaccine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611076819.1A CN106540250A (en) | 2016-11-30 | 2016-11-30 | The preparation method of goose source reovirus inactivated vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106540250A true CN106540250A (en) | 2017-03-29 |
Family
ID=58396518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611076819.1A Pending CN106540250A (en) | 2016-11-30 | 2016-11-30 | The preparation method of goose source reovirus inactivated vaccine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106540250A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107586333A (en) * | 2017-09-30 | 2018-01-16 | 天津瑞普生物技术股份有限公司 | A kind of multi-joint Yolk antibody preparation method for aquatic bird |
| CN108676092A (en) * | 2018-05-22 | 2018-10-19 | 山东农业大学 | A kind of Yolk antibody and preparation method thereof of prevention novel duck reovirus |
| CN108912227A (en) * | 2018-08-10 | 2018-11-30 | 山东农业大学 | A kind of Yolk antibody and its preparation method and application of anti-duck reovirus |
| CN108982847A (en) * | 2018-08-10 | 2018-12-11 | 山东农业大学 | A kind of indirect ELISA detection method for the duck reovirus leading to duck spleen necrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895667A (en) * | 2006-06-06 | 2007-01-17 | 瑞普（保定）生物药业有限公司 | Reovirus inactivated vaccine and its preparation |
| CN103479997A (en) * | 2013-09-23 | 2014-01-01 | 天津瑞普生物技术股份有限公司 | Preparation method for avian reovirus virus water-in-oil-in-water type inactivated vaccines |
-
2016
- 2016-11-30 CN CN201611076819.1A patent/CN106540250A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1895667A (en) * | 2006-06-06 | 2007-01-17 | 瑞普（保定）生物药业有限公司 | Reovirus inactivated vaccine and its preparation |
| CN103479997A (en) * | 2013-09-23 | 2014-01-01 | 天津瑞普生物技术股份有限公司 | Preparation method for avian reovirus virus water-in-oil-in-water type inactivated vaccines |
Non-Patent Citations (2)
| Title |
|---|
| 杨瑞: "致鸭产蛋下降的呼肠孤病毒ZY/AH/1/2011株的分离、鉴定及油乳剂灭活疫苗研制", 《中国优秀硕士学位论文全文数据库》 * |
| 陈红梅等: "雏鹅呼肠孤病毒的分离与鉴定", 《第三届水禽疫病防控研讨会》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107586333A (en) * | 2017-09-30 | 2018-01-16 | 天津瑞普生物技术股份有限公司 | A kind of multi-joint Yolk antibody preparation method for aquatic bird |
| CN107586333B (en) * | 2017-09-30 | 2019-11-22 | 天津瑞普生物技术股份有限公司 | A kind of multi-joint Yolk antibody preparation method for aquatic bird |
| CN108676092A (en) * | 2018-05-22 | 2018-10-19 | 山东农业大学 | A kind of Yolk antibody and preparation method thereof of prevention novel duck reovirus |
| CN108912227A (en) * | 2018-08-10 | 2018-11-30 | 山东农业大学 | A kind of Yolk antibody and its preparation method and application of anti-duck reovirus |
| CN108982847A (en) * | 2018-08-10 | 2018-12-11 | 山东农业大学 | A kind of indirect ELISA detection method for the duck reovirus leading to duck spleen necrosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106540250A (en) | The preparation method of goose source reovirus inactivated vaccine | |
| Quast et al. | Serological evidence for the presence of influenza D virus in small ruminants | |
| Bertran et al. | Pathogenesis and transmissibility of highly (H7N1) and low (H7N9) pathogenic avian influenza virus infection in red-legged partridge (Alectoris rufa) | |
| Wood et al. | Standardization of inactivated H5N2 influenza vaccine and efficacy against lethal A/Chicken/Pennsylvania/1370/83 infection | |
| Wanaratana et al. | Experimental assessment of houseflies as vectors in avian influenza subtype H5N1 transmission in chickens | |
| Koethe et al. | Modulation of lethal HPAIV H5N8 clade 2.3. 4.4 B infection in AIV pre-exposed mallards | |
| Sivanandan et al. | Isolation of H13N2 influenza A virus from turkeys and surface water | |
| Zeng et al. | Protective efficacy of an H5/H7 trivalent inactivated vaccine (H5-Re13, H5-Re14, and H7-Re4 strains) in chickens, ducks, and geese against newly detected H5N1, H5N6, H5N8, and H7N9 viruses | |
| CN106967781A (en) | It is a kind of to be used to detect the method that electronics tobacco product influences reverse mutation number | |
| CN101942419B (en) | Dog parvovirus attenuated vaccine strain and application thereof | |
| CN101423548B (en) | Preparation of duck hepatitis I type virus indirect hemagglutination diagnostic antigen and kit | |
| CN104374914B (en) | A kind of pseudomonas putida test strip and preparation method thereof | |
| Gharaibeh et al. | Vaccine efficacy against a new avian influenza (H9N2) field isolate from the Middle East (serology and challenge studies) | |
| Tabynov et al. | Immunogenic and protective properties of the first Kazakhstan vaccine against pandemic influenza A (H1N1) pdm09 in ferrets | |
| CN105203757B (en) | A kind of colloidal gold strip of quick diagnosis tembusu virus | |
| Reis et al. | Tenacity of low-pathogenic avian influenza viruses in different types of poultry litter | |
| Woolcock et al. | Isolation of avian influenza virus (H10N7) from an emu (Dromaius novaehollandiae) with conjunctivitis and respiratory disease | |
| CN105445457A (en) | Porcine circovirus II competition ELISA antibody detection kit | |
| CN114788521B (en) | Composite synergistic multifunctional disinfectant and preparation method thereof | |
| CN101025420A (en) | Avian influenza virus latex agglutination assay kit and its use | |
| CN105866434A (en) | Immunochromatography kit for detecting IgM antibodies of nine respiratory tract infection pathogens and preparation method thereof | |
| CN103396999B (en) | H9N2 subtype virus, H9N2 hypotype disease vaccine and preparation method thereof | |
| CN105039270B (en) | H9N2 subtype avian influenza acclimatization to cold attenuated strains and its application | |
| Jadidi et al. | Optimizing the process of inactivating influenza virus subtype H9N2 by formalin in the production of killed avian influenza vaccine. | |
| Shivaprasad et al. | Genetic and antigenic characterization of a poxvirus isolate from ostriches |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170329 |